Quality assurance for the EORTC 22071–26071 study: dummy run prospective analysis

The phase III 22071-26071 trial was designed to evaluate the addition of panitumumab to adjuvant chemotherapy plus intensity modulated radiotherapy (IMRT) in locally advanced resected squamous cell head and neck cancer. We report the results of the dummy run (DR) performed to detect deviations from protocol guidelines.DR datasets consisting of target volumes, organs at risk (OAR) and treatment plans were digitally uploaded, then compared with...